Post transplant lymphoproliferative / lymphoproliferation disorder (PTLD)

Post transplant lymphoproliferative/lymphoproliferation disorder (PTLD) is increasing in prevalence as the number and survival length of solid organ and bone-marrow transplant recipients also increases.

It represents a variety of conditions varying from lymphoid hyperplasia to malignancy but is included in the 2008 WHO classification of tumours of haematopoietic and lymphoid tissues. PTLD can be a life threatening fulminant disorder and affects ~10% of solid organ transplant recipients. 

PTLD develops in no more than 2% of all patients who receive transplants, somewhat higher in paediatric patients 10. It is the second most common type of malignancy in post transplant patients with two peaks demonstrated - firstly at one-year post transplant and secondly at 4-5 years post transplant 13. The incidence varies according to the type of transplant 3,4,10 :

Risk factors

A number of risk factors are recognised including 11

  • Epstein-Barr virus seronegativity at the time of transplantation (which may explain why the incidence of PTLD is higher in children)
  • concomitant cytomegalovirus infection
  • allograft type

The immunosuppressive regime also affects the distribution of PTLD: 

  • azathioprine: more common CNS and allograft involvement 
  • cyclosporin or FK-506: gastrointestinal tract and lymph nodes

Clinical presentation is variable, both in symptomatology and severity, ranging from flu-like symptoms with fever and malaise to fulminant systemic disease 3. It of course also varies with the location of the PTLD (see below).

The time between transplant and development of PTLD is also variable, ranging from 1 month to 7 years 4,9, with most occurring within a year 9. As a general rule patients who present late (>1 year) have more aggressive tumours with poorer prognosis 6

Most PTLD specimens demonstrate a polyclonal B-cell Epstien-Barr virus (EBV) positive cell population 3. Monoclonal B-cell and T-cell small bowel lymphomas do occur in patients with organ transplants but are less common.

When PTLD develops in haematopoietic stem cell transplant recipients it is usually from the donor 7.

Macroscopic appearance

Macroscopically these tumours have been likened to uncooked fish flesh1.

Histology

These tumours range from low-grade/benign lymphoid hyperplasia to high grade malignant non-Hodgkin's lymphoma (NHL).

Location

PTLD may be focal or diffuse and can affect almost any organ system and even the allograft. It usually manifests as extranodal disease, and can occur in a variety of locations, including 8-9:

The range of appearances is large due to the number of possible sites. In general extranodal involvement is 3-4 times more common than nodal involvement, and resembles primary lymphoma of those organs 9:

  • solid organs (liver, spleen, kidney)
    • nodules
      • hypoechoic
      • low density on CT
    • diffuse infiltration
  • bowel
    • circumferential wall thickening
    • aneurysmal dilatation
    • ulceration/perforation
    • bowel obstruction uncommon
  • lung
    • nodules
      • usually homogeneous
      • may centrally cavitate
    • diffuse infiltration
  • brain
    • similar to lymphoma in the setting of HIV infection
    • necrosis and haemorrhage more common than in run-of-the-mill primary CNS lymphoma
  • nodes
    • non-specific nodal enlargement, similar to other lymphomas
    • most commonly affecting mediastinum (either lymphadenopathy or anterior mediastinal mass) or retroperitoneum (either as lymphadenopathy or mass) 13

Treatment is variable, and depends on the location and extent of disease. Options include 6,8:

  • reduction of immunosuppression
  • surgical resection of localised disease
  • radiotherapy
  • medical agents
    • alpha interferon therapy
    • antiviral therapy (limited success)
    • IL-2 infusions
    • rituximab

Prognosis depends on the grade of the lymphoma, and cell type: low grade lymphoid proliferation of polyclonal B-cell origin with EBV implication have better prognosis, than other cell types of higher grade. Five-year survival is ~ 35% 7.

Disease regression in response to a reduction in immunosuppression is a unique diagnostic feature of PTLD and distinguishes this condition from other malignant diseases. Patients should be closely monitored for allograft rejection. 

The differential diagnosis would depend on the location of PTLD and is therefore broad:


Lymphoma
Share article

Article Information

rID: 7059
Section: Pathology
Synonyms or Alternate Spellings:
  • PTLD
  • Post transplant lymphoproliferative disorder (PTLD)
  • Post-transplant lymphoproliferation disorders
  • Post transplant lymphoproliferative disorder

Support Radiopaedia and see fewer ads

Cases and Figures

  • Drag
    Case 1: small bowel
    Drag here to reorder.
  • Drag
    Case 2: sinuses
    Drag here to reorder.
  • Drag
    Case 3: small bowel
    Drag here to reorder.
  • Drag
    Case 3: small bowel
    Drag here to reorder.
  • Drag
    PTLD
    Case 4
    Drag here to reorder.
  • Updating… Please wait.
    Loadinganimation

    Alert accept

    Error Unable to process the form. Check for errors and try again.

    Alert accept Thank you for updating your details.